Why the study?
Can MDM2 and Ki-67 immunohistochemistry distinguish well-differentiated liposarcoma from spindle cell lipoma in a recurrent orbital tumor?
Can MDM2 and Ki-67 immunohistochemistry distinguish well-differentiated liposarcoma from spindle cell lipoma in a recurrent orbital tumor?
MDM2 gene amplification and Ki-67 proliferation index can reliably distinguish well-differentiated liposarcoma from benign spindle cell or atypical lipoma in orbital tumors.
Answers are grounded in this paper and cite their sources.
MDM2/Ki-67 testing may aid orbital lipomatous tumor diagnosis; single case report leaves broader validation open.
In Brief Purpose: To distinguish, in a 36-year-old man, an atypical lipomatous neoplasm/well-differentiated liposarcoma from a spindle cell lipoma in a recurrent orbital tumor. Methods: Clinical, radiographic, and histopathologic evaluations coupled with immunohistochemical studies for CD34, factor XIII, bcl-2, S-100, muscle-specific actin, Ki-67, and MDM2. Results: MDM2 gene amplification was discovered in the CD34+ tumor cells. An average Ki-67 proliferation index of 28% was ascertained for the original and recurrent lesions. These findings established the diagnosis of a well-differentiated liposarcoma with lipoma-like and spindle cell features and ruled out a spindle cell lipoma. Conclusion: Well-differentiated liposarcoma is a slow growing, infiltrative, and nonmetastasizing neoplasm that is microscopically and diagnostically challenging. It can be reliably separated from a benign spindle cell or an atypical lipoma by using the markers MDM2 and Ki-67. A recurrent well-differentiated lipomatous orbital tumor in a 36-year-old man was diagnosed as a liposarcoma by using immunohistochemistry to identify MDM2 gene amplification and a high Ki-67 proliferation index.
No takes yet. Share an insight, caveat, or question.
Jakobiec et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: